|
Synonyms: dalteparin sodium | Fragmin®
dalteparin is an approved drug (FDA (1994))
Compound class:
Synthetic organic
Comment: An antithrombin-III activator. Since this drug is a mixture of hydrolysed fragments of porcine herparin, a chemical structure is not shown.
View more information in the IUPHAR Pharmacology Education Project: dalteparin |
| No information available. |
Summary of Clinical Use  |
| Used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in various at-risk groups of patients (e.g. those undergoing general surgery, with acute medical conditions, severely restricted mobility or undergoing hemodialysis or hemofiltration). In May 2019, the FDA approved dalteparin's use in paediatric patients ≥1 month of age, to reduce the recurrence of symptomatic venous thromboembolism (VTE), based on findings from clinical trial NCT00952380. This was the first FDA approval of a drug to manage VTE in paediatric patients. |
| Mechanism Of Action and Pharmacodynamic Effects |
| A low molecular weight heparin (LMWH, MW 2000-9000 Da), anticoagulant |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00952380 | Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients | Phase 2 Interventional | Pfizer | ||
